| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pharmacogenetics | 45 | 2026 | 472 | 13.910 |
Why?
|
| Pharmacogenomic Testing | 18 | 2026 | 119 | 7.810 |
Why?
|
| Carcinoma, Transitional Cell | 25 | 2026 | 158 | 6.720 |
Why?
|
| Precision Medicine | 18 | 2026 | 503 | 4.450 |
Why?
|
| Urologic Neoplasms | 20 | 2026 | 82 | 4.290 |
Why?
|
| Urinary Bladder Neoplasms | 22 | 2026 | 401 | 3.990 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 7 | 2022 | 220 | 2.730 |
Why?
|
| Decision Support Systems, Clinical | 6 | 2025 | 132 | 2.500 |
Why?
|
| Antibodies, Monoclonal, Humanized | 19 | 2026 | 1099 | 2.240 |
Why?
|
| Cisplatin | 19 | 2026 | 578 | 2.210 |
Why?
|
| Drug Prescriptions | 6 | 2025 | 158 | 2.180 |
Why?
|
| Antineoplastic Agents | 24 | 2025 | 2373 | 2.120 |
Why?
|
| Patient Portals | 3 | 2025 | 36 | 2.050 |
Why?
|
| Antibodies, Monoclonal | 17 | 2026 | 1416 | 2.040 |
Why?
|
| Prescription Drugs | 3 | 2025 | 42 | 1.970 |
Why?
|
| Pharmacogenomic Variants | 4 | 2021 | 46 | 1.960 |
Why?
|
| Neoplasms | 13 | 2025 | 3340 | 1.670 |
Why?
|
| Perioperative Care | 7 | 2026 | 198 | 1.640 |
Why?
|
| Practice Patterns, Physicians' | 6 | 2025 | 659 | 1.570 |
Why?
|
| Immunoconjugates | 3 | 2026 | 138 | 1.550 |
Why?
|
| Antimetabolites, Antineoplastic | 7 | 2024 | 246 | 1.460 |
Why?
|
| Humans | 132 | 2026 | 98088 | 1.400 |
Why?
|
| Clinical Decision-Making | 5 | 2021 | 305 | 1.290 |
Why?
|
| Biomarkers, Tumor | 8 | 2025 | 1764 | 1.270 |
Why?
|
| Capecitabine | 7 | 2024 | 103 | 1.240 |
Why?
|
| Aged | 52 | 2026 | 21758 | 1.240 |
Why?
|
| Middle Aged | 58 | 2026 | 29428 | 1.200 |
Why?
|
| Prospective Studies | 15 | 2025 | 4823 | 1.150 |
Why?
|
| Decision Support Techniques | 2 | 2021 | 194 | 1.150 |
Why?
|
| Polymorphism, Single Nucleotide | 10 | 2025 | 2558 | 1.150 |
Why?
|
| Aged, 80 and over | 30 | 2026 | 7389 | 1.140 |
Why?
|
| Anesthesiology | 2 | 2022 | 171 | 1.110 |
Why?
|
| Genotype | 11 | 2023 | 1888 | 1.100 |
Why?
|
| Male | 63 | 2026 | 47077 | 1.100 |
Why?
|
| Health Knowledge, Attitudes, Practice | 3 | 2026 | 601 | 1.050 |
Why?
|
| Female | 62 | 2026 | 51541 | 1.030 |
Why?
|
| Adult | 45 | 2026 | 29539 | 0.990 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2020 | 314 | 0.910 |
Why?
|
| Antineoplastic Agents, Immunological | 5 | 2024 | 237 | 0.860 |
Why?
|
| Genomics | 5 | 2022 | 898 | 0.850 |
Why?
|
| Cardiovascular Agents | 2 | 2015 | 62 | 0.850 |
Why?
|
| Urothelium | 5 | 2023 | 67 | 0.830 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 7 | 2016 | 977 | 0.800 |
Why?
|
| Point-of-Care Systems | 3 | 2019 | 155 | 0.740 |
Why?
|
| Referral and Consultation | 1 | 2026 | 418 | 0.740 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 13 | 2026 | 2658 | 0.720 |
Why?
|
| Tramadol | 1 | 2022 | 14 | 0.710 |
Why?
|
| Patient Care Team | 1 | 2025 | 320 | 0.710 |
Why?
|
| Kidney Neoplasms | 5 | 2021 | 556 | 0.710 |
Why?
|
| Hepatic Veno-Occlusive Disease | 2 | 2012 | 20 | 0.680 |
Why?
|
| Busulfan | 2 | 2012 | 41 | 0.680 |
Why?
|
| Germ-Line Mutation | 4 | 2020 | 402 | 0.670 |
Why?
|
| Anesthetics | 1 | 2021 | 51 | 0.670 |
Why?
|
| Platinum | 5 | 2023 | 68 | 0.660 |
Why?
|
| Pain Management | 2 | 2021 | 194 | 0.660 |
Why?
|
| B7-H1 Antigen | 9 | 2022 | 332 | 0.640 |
Why?
|
| Rheumatology | 1 | 2021 | 47 | 0.640 |
Why?
|
| Patient Education as Topic | 2 | 2026 | 417 | 0.630 |
Why?
|
| Analgesics | 1 | 2021 | 131 | 0.630 |
Why?
|
| Anesthesia | 1 | 2022 | 175 | 0.620 |
Why?
|
| Carcinoma, Renal Cell | 3 | 2021 | 384 | 0.590 |
Why?
|
| Medication Adherence | 1 | 2020 | 130 | 0.570 |
Why?
|
| Drug Labeling | 2 | 2017 | 44 | 0.570 |
Why?
|
| Information Dissemination | 1 | 2019 | 133 | 0.550 |
Why?
|
| Drug Therapy | 2 | 2018 | 67 | 0.550 |
Why?
|
| Deoxycytidine | 2 | 2026 | 217 | 0.550 |
Why?
|
| Pharmacology, Clinical | 1 | 2018 | 9 | 0.540 |
Why?
|
| Quinazolines | 2 | 2016 | 221 | 0.540 |
Why?
|
| Cardiovascular Diseases | 2 | 2015 | 802 | 0.530 |
Why?
|
| Benzamides | 4 | 2025 | 260 | 0.520 |
Why?
|
| Follow-Up Studies | 12 | 2026 | 4025 | 0.520 |
Why?
|
| Medical Order Entry Systems | 1 | 2017 | 30 | 0.510 |
Why?
|
| Surveys and Questionnaires | 5 | 2026 | 3022 | 0.510 |
Why?
|
| Germ Cells | 2 | 2022 | 137 | 0.500 |
Why?
|
| Inpatients | 3 | 2025 | 369 | 0.500 |
Why?
|
| Patient Care | 1 | 2018 | 99 | 0.500 |
Why?
|
| Vidarabine | 3 | 2012 | 107 | 0.490 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 3 | 2025 | 117 | 0.490 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 3 | 1 | 2016 | 22 | 0.480 |
Why?
|
| Analgesics, Opioid | 1 | 2021 | 540 | 0.480 |
Why?
|
| Fluorouracil | 2 | 2023 | 541 | 0.480 |
Why?
|
| Genome, Human | 3 | 2019 | 832 | 0.480 |
Why?
|
| Receptor, ErbB-3 | 1 | 2016 | 19 | 0.470 |
Why?
|
| Physician-Patient Relations | 2 | 2019 | 580 | 0.460 |
Why?
|
| Physician's Role | 1 | 2017 | 181 | 0.450 |
Why?
|
| Critical Care | 1 | 2019 | 483 | 0.450 |
Why?
|
| Clinical Medicine | 1 | 2015 | 27 | 0.450 |
Why?
|
| Cytochrome P-450 CYP2D6 | 3 | 2022 | 53 | 0.450 |
Why?
|
| Clinical Trials, Phase II as Topic | 4 | 2014 | 168 | 0.440 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2015 | 82 | 0.440 |
Why?
|
| Collagen Type I | 1 | 2015 | 75 | 0.440 |
Why?
|
| Snake Venoms | 2 | 2015 | 10 | 0.440 |
Why?
|
| Quality of Life | 7 | 2024 | 1895 | 0.440 |
Why?
|
| Patient Selection | 3 | 2018 | 726 | 0.430 |
Why?
|
| Phenylthiohydantoin | 2 | 2025 | 57 | 0.430 |
Why?
|
| Academic Medical Centers | 2 | 2015 | 413 | 0.430 |
Why?
|
| Genetic Predisposition to Disease | 5 | 2025 | 2555 | 0.420 |
Why?
|
| Programmed Cell Death 1 Receptor | 5 | 2022 | 199 | 0.420 |
Why?
|
| Pyrroles | 2 | 2015 | 165 | 0.420 |
Why?
|
| Nectins | 3 | 2022 | 8 | 0.410 |
Why?
|
| Transplantation Conditioning | 4 | 2014 | 388 | 0.400 |
Why?
|
| Cystectomy | 3 | 2026 | 124 | 0.400 |
Why?
|
| Treatment Outcome | 19 | 2025 | 9711 | 0.400 |
Why?
|
| Cardiology | 1 | 2015 | 124 | 0.400 |
Why?
|
| Neovascularization, Pathologic | 1 | 2015 | 356 | 0.390 |
Why?
|
| Indoles | 2 | 2015 | 334 | 0.390 |
Why?
|
| Ambulatory Care | 2 | 2014 | 201 | 0.390 |
Why?
|
| Program Development | 1 | 2014 | 141 | 0.390 |
Why?
|
| Inflammation | 1 | 2019 | 1120 | 0.380 |
Why?
|
| Biomarkers, Pharmacological | 1 | 2012 | 21 | 0.370 |
Why?
|
| Hematologic Neoplasms | 4 | 2016 | 383 | 0.370 |
Why?
|
| Pain | 4 | 2024 | 416 | 0.370 |
Why?
|
| Stomach Neoplasms | 1 | 2015 | 319 | 0.360 |
Why?
|
| Mutation | 6 | 2020 | 4396 | 0.360 |
Why?
|
| Chicago | 6 | 2026 | 1513 | 0.350 |
Why?
|
| Peptides | 1 | 2015 | 669 | 0.350 |
Why?
|
| Young Adult | 7 | 2025 | 7507 | 0.350 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2016 | 640 | 0.350 |
Why?
|
| Dose-Response Relationship, Drug | 6 | 2024 | 1950 | 0.340 |
Why?
|
| Neoplasm Staging | 7 | 2021 | 2080 | 0.330 |
Why?
|
| Pharmaceutical Preparations | 1 | 2012 | 109 | 0.330 |
Why?
|
| Kidney Failure, Chronic | 2 | 2016 | 445 | 0.330 |
Why?
|
| Patient Reported Outcome Measures | 3 | 2024 | 336 | 0.330 |
Why?
|
| Patient Safety | 4 | 2023 | 235 | 0.320 |
Why?
|
| Cell Adhesion Molecules | 2 | 2022 | 184 | 0.320 |
Why?
|
| Prognosis | 12 | 2020 | 4116 | 0.320 |
Why?
|
| Antibodies, Neoplasm | 1 | 2010 | 87 | 0.320 |
Why?
|
| Drug Delivery Systems | 1 | 2012 | 200 | 0.310 |
Why?
|
| Hemoglobinopathies | 1 | 2010 | 9 | 0.310 |
Why?
|
| Carcinoma | 3 | 2021 | 440 | 0.310 |
Why?
|
| Neoplasm Metastasis | 7 | 2024 | 1089 | 0.310 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2011 | 665 | 0.300 |
Why?
|
| Kidney Medulla | 1 | 2010 | 79 | 0.300 |
Why?
|
| United States | 7 | 2025 | 8197 | 0.300 |
Why?
|
| BK Virus | 1 | 2009 | 23 | 0.300 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2017 | 1536 | 0.300 |
Why?
|
| Polyomavirus Infections | 1 | 2009 | 29 | 0.300 |
Why?
|
| Urinary Bladder | 4 | 2026 | 261 | 0.290 |
Why?
|
| Brain Neoplasms | 1 | 2015 | 839 | 0.290 |
Why?
|
| Hematuria | 1 | 2009 | 51 | 0.290 |
Why?
|
| Tumor Virus Infections | 1 | 2009 | 83 | 0.290 |
Why?
|
| Carboplatin | 6 | 2016 | 331 | 0.290 |
Why?
|
| Pyrimidines | 3 | 2018 | 413 | 0.290 |
Why?
|
| Warfarin | 2 | 2019 | 108 | 0.280 |
Why?
|
| Neoplasm Invasiveness | 7 | 2026 | 582 | 0.280 |
Why?
|
| Disease Susceptibility | 1 | 2009 | 226 | 0.280 |
Why?
|
| Genetic Variation | 3 | 2014 | 1445 | 0.280 |
Why?
|
| Genetic Testing | 4 | 2019 | 594 | 0.270 |
Why?
|
| Breast Neoplasms | 2 | 2020 | 3272 | 0.270 |
Why?
|
| Anemia, Sickle Cell | 1 | 2010 | 158 | 0.260 |
Why?
|
| Risk Assessment | 3 | 2021 | 2585 | 0.260 |
Why?
|
| Nitriles | 2 | 2025 | 171 | 0.250 |
Why?
|
| Kidney Diseases | 1 | 2009 | 314 | 0.250 |
Why?
|
| Models, Genetic | 1 | 2012 | 1005 | 0.240 |
Why?
|
| Cohort Studies | 4 | 2019 | 3212 | 0.240 |
Why?
|
| Sulfotransferases | 1 | 2025 | 16 | 0.230 |
Why?
|
| Genotyping Techniques | 2 | 2018 | 72 | 0.230 |
Why?
|
| Risk Factors | 5 | 2021 | 6233 | 0.230 |
Why?
|
| Transplantation, Homologous | 7 | 2020 | 1026 | 0.230 |
Why?
|
| Kidney | 1 | 2011 | 1123 | 0.230 |
Why?
|
| Androstenes | 1 | 2025 | 41 | 0.230 |
Why?
|
| Sirolimus | 1 | 2006 | 182 | 0.230 |
Why?
|
| Oncologists | 1 | 2025 | 43 | 0.220 |
Why?
|
| Genome-Wide Association Study | 9 | 2025 | 1850 | 0.220 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2019 | 1012 | 0.210 |
Why?
|
| Neuroendocrine Tumors | 1 | 2006 | 157 | 0.210 |
Why?
|
| Polymorphism, Genetic | 3 | 2015 | 831 | 0.210 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2025 | 94 | 0.210 |
Why?
|
| Tertiary Care Centers | 2 | 2016 | 131 | 0.210 |
Why?
|
| Angiogenesis Inhibitors | 2 | 2016 | 280 | 0.200 |
Why?
|
| Survival Analysis | 6 | 2023 | 1527 | 0.200 |
Why?
|
| Medical Oncology | 2 | 2022 | 421 | 0.200 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2024 | 54 | 0.200 |
Why?
|
| Insurance Coverage | 1 | 2025 | 152 | 0.200 |
Why?
|
| Insurance, Health | 1 | 2025 | 186 | 0.200 |
Why?
|
| Adolescent | 8 | 2025 | 10080 | 0.190 |
Why?
|
| Neutropenia | 1 | 2023 | 211 | 0.190 |
Why?
|
| Patient Participation | 1 | 2025 | 246 | 0.190 |
Why?
|
| Alemtuzumab | 3 | 2012 | 90 | 0.190 |
Why?
|
| Adenine Nucleotides | 2 | 2014 | 57 | 0.190 |
Why?
|
| Arabinonucleosides | 2 | 2014 | 37 | 0.190 |
Why?
|
| Proprotein Convertase 9 | 1 | 2023 | 37 | 0.190 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2023 | 88 | 0.190 |
Why?
|
| Receptors, Glucocorticoid | 1 | 2024 | 145 | 0.190 |
Why?
|
| Thrombocytopenia | 1 | 2023 | 194 | 0.180 |
Why?
|
| Hospitalization | 2 | 2019 | 991 | 0.180 |
Why?
|
| Fenretinide | 1 | 2002 | 2 | 0.180 |
Why?
|
| Omeprazole | 1 | 2022 | 11 | 0.180 |
Why?
|
| Succinylcholine | 1 | 2022 | 14 | 0.180 |
Why?
|
| Ceramides | 1 | 2002 | 36 | 0.180 |
Why?
|
| Hydralazine | 1 | 2022 | 22 | 0.180 |
Why?
|
| Serine Endopeptidases | 1 | 2023 | 154 | 0.180 |
Why?
|
| Oxycodone | 1 | 2022 | 35 | 0.170 |
Why?
|
| Sulfonamides | 2 | 2016 | 351 | 0.170 |
Why?
|
| Lymphocytes | 3 | 2010 | 461 | 0.170 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2024 | 212 | 0.170 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2026 | 525 | 0.170 |
Why?
|
| Patient Readmission | 1 | 2025 | 425 | 0.170 |
Why?
|
| Muscles | 1 | 2021 | 179 | 0.160 |
Why?
|
| Practice Guidelines as Topic | 2 | 2018 | 1110 | 0.160 |
Why?
|
| Ferredoxin-NADP Reductase | 1 | 2020 | 15 | 0.160 |
Why?
|
| Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2020 | 28 | 0.160 |
Why?
|
| Disease-Free Survival | 6 | 2021 | 1193 | 0.150 |
Why?
|
| Pyrazines | 1 | 2020 | 98 | 0.150 |
Why?
|
| Research | 2 | 2019 | 257 | 0.150 |
Why?
|
| Clinical Trials as Topic | 2 | 2016 | 1129 | 0.150 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 1 | 2022 | 196 | 0.150 |
Why?
|
| Drug Recalls | 1 | 2019 | 12 | 0.150 |
Why?
|
| Codeine | 1 | 2019 | 12 | 0.150 |
Why?
|
| Health Plan Implementation | 1 | 2019 | 62 | 0.150 |
Why?
|
| CREB-Binding Protein | 1 | 2018 | 16 | 0.140 |
Why?
|
| E1A-Associated p300 Protein | 1 | 2018 | 15 | 0.140 |
Why?
|
| Predictive Value of Tests | 2 | 2021 | 1782 | 0.140 |
Why?
|
| Phenotype | 3 | 2019 | 2638 | 0.140 |
Why?
|
| Survival Rate | 3 | 2018 | 2041 | 0.140 |
Why?
|
| Pilot Projects | 2 | 2019 | 977 | 0.140 |
Why?
|
| Evidence-Based Medicine | 1 | 2021 | 480 | 0.140 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2021 | 1394 | 0.140 |
Why?
|
| Acute Kidney Injury | 2 | 2014 | 372 | 0.140 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 4 | 2021 | 61 | 0.140 |
Why?
|
| Tumor Burden | 1 | 2019 | 333 | 0.140 |
Why?
|
| Electronic Health Records | 2 | 2025 | 442 | 0.130 |
Why?
|
| Infusions, Intravenous | 3 | 2017 | 412 | 0.130 |
Why?
|
| Neoadjuvant Therapy | 2 | 2026 | 478 | 0.130 |
Why?
|
| Program Evaluation | 1 | 2019 | 346 | 0.130 |
Why?
|
| Guidelines as Topic | 1 | 2019 | 169 | 0.130 |
Why?
|
| Vinca Alkaloids | 2 | 2025 | 4 | 0.130 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2002 | 443 | 0.130 |
Why?
|
| Tumor Microenvironment | 2 | 2022 | 618 | 0.130 |
Why?
|
| Abdominal Neoplasms | 1 | 2017 | 38 | 0.130 |
Why?
|
| Radiosurgery | 1 | 2021 | 351 | 0.130 |
Why?
|
| Standard of Care | 1 | 2017 | 70 | 0.120 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2018 | 168 | 0.120 |
Why?
|
| Organoplatinum Compounds | 2 | 2019 | 95 | 0.120 |
Why?
|
| User-Computer Interface | 1 | 2017 | 194 | 0.120 |
Why?
|
| Social Perception | 1 | 2017 | 93 | 0.120 |
Why?
|
| Drug Therapy, Computer-Assisted | 1 | 2016 | 7 | 0.120 |
Why?
|
| Disease Management | 1 | 2019 | 377 | 0.120 |
Why?
|
| Health Personnel | 1 | 2019 | 257 | 0.120 |
Why?
|
| Safety | 1 | 2017 | 138 | 0.120 |
Why?
|
| Tissue Donors | 1 | 2020 | 581 | 0.120 |
Why?
|
| Chemoradiotherapy | 1 | 2018 | 337 | 0.120 |
Why?
|
| Benzodioxoles | 1 | 2015 | 15 | 0.120 |
Why?
|
| Anticoagulants | 1 | 2019 | 486 | 0.120 |
Why?
|
| Hospital Mortality | 1 | 2019 | 541 | 0.120 |
Why?
|
| Liver | 3 | 2022 | 1231 | 0.110 |
Why?
|
| Attitude to Health | 1 | 2017 | 217 | 0.110 |
Why?
|
| Case-Control Studies | 1 | 2020 | 1995 | 0.110 |
Why?
|
| Transcription Factor RelA | 1 | 2015 | 39 | 0.110 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2015 | 58 | 0.110 |
Why?
|
| Universities | 2 | 2013 | 166 | 0.110 |
Why?
|
| 5' Untranslated Regions | 1 | 2015 | 52 | 0.110 |
Why?
|
| Forecasting | 1 | 2016 | 295 | 0.110 |
Why?
|
| Communication | 1 | 2019 | 455 | 0.110 |
Why?
|
| G(M2) Ganglioside | 1 | 2015 | 3 | 0.110 |
Why?
|
| Tay-Sachs Disease | 1 | 2015 | 6 | 0.110 |
Why?
|
| Response Elements | 1 | 2015 | 68 | 0.110 |
Why?
|
| Tunica Intima | 1 | 2015 | 61 | 0.110 |
Why?
|
| Area Under Curve | 2 | 2014 | 340 | 0.110 |
Why?
|
| Survivors | 1 | 2016 | 213 | 0.110 |
Why?
|
| Drug Administration Schedule | 3 | 2026 | 839 | 0.110 |
Why?
|
| Ureter | 1 | 2016 | 80 | 0.110 |
Why?
|
| Fatal Outcome | 1 | 2015 | 296 | 0.110 |
Why?
|
| Immunotherapy | 2 | 2020 | 821 | 0.110 |
Why?
|
| Maximum Tolerated Dose | 2 | 2017 | 265 | 0.110 |
Why?
|
| Epilepsies, Myoclonic | 1 | 2015 | 26 | 0.110 |
Why?
|
| Data Interpretation, Statistical | 1 | 2016 | 313 | 0.100 |
Why?
|
| Nomograms | 1 | 2014 | 34 | 0.100 |
Why?
|
| Attitude of Health Personnel | 1 | 2019 | 685 | 0.100 |
Why?
|
| Exome | 1 | 2014 | 145 | 0.100 |
Why?
|
| Kidney Transplantation | 2 | 2016 | 939 | 0.100 |
Why?
|
| Genetic Markers | 1 | 2014 | 471 | 0.100 |
Why?
|
| Radiography | 1 | 2015 | 764 | 0.100 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2018 | 699 | 0.100 |
Why?
|
| Liver Neoplasms | 2 | 2017 | 831 | 0.100 |
Why?
|
| Total Quality Management | 1 | 2013 | 31 | 0.100 |
Why?
|
| Receptors, Cell Surface | 1 | 2014 | 291 | 0.100 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2026 | 903 | 0.100 |
Why?
|
| Software | 1 | 2017 | 693 | 0.100 |
Why?
|
| Muscle Neoplasms | 1 | 2013 | 16 | 0.100 |
Why?
|
| Endothelium, Vascular | 1 | 2015 | 440 | 0.100 |
Why?
|
| Endonucleases | 1 | 2012 | 22 | 0.090 |
Why?
|
| Workflow | 1 | 2013 | 85 | 0.090 |
Why?
|
| Fanconi Anemia | 1 | 2012 | 10 | 0.090 |
Why?
|
| Genetics, Medical | 1 | 2013 | 51 | 0.090 |
Why?
|
| DNA Repair | 1 | 2014 | 363 | 0.090 |
Why?
|
| Delivery of Health Care | 1 | 2017 | 480 | 0.090 |
Why?
|
| Biopsy | 2 | 2016 | 1224 | 0.090 |
Why?
|
| Lymphocyte Depletion | 1 | 2012 | 103 | 0.090 |
Why?
|
| Atherosclerosis | 1 | 2015 | 266 | 0.090 |
Why?
|
| Models, Statistical | 1 | 2016 | 601 | 0.090 |
Why?
|
| Combined Modality Therapy | 3 | 2024 | 1751 | 0.090 |
Why?
|
| High-Throughput Nucleotide Sequencing | 3 | 2022 | 568 | 0.090 |
Why?
|
| Disease Progression | 3 | 2016 | 1610 | 0.090 |
Why?
|
| Blood Glucose | 1 | 2016 | 911 | 0.090 |
Why?
|
| Time Factors | 3 | 2016 | 5567 | 0.090 |
Why?
|
| Decision Making | 1 | 2017 | 686 | 0.090 |
Why?
|
| Fibroblasts | 1 | 2015 | 767 | 0.090 |
Why?
|
| Graft vs Host Disease | 2 | 2012 | 379 | 0.090 |
Why?
|
| Melphalan | 1 | 2011 | 98 | 0.090 |
Why?
|
| Databases, Factual | 1 | 2016 | 1094 | 0.090 |
Why?
|
| Biomedical Research | 2 | 2013 | 471 | 0.090 |
Why?
|
| T-Lymphocytes | 2 | 2022 | 1331 | 0.080 |
Why?
|
| HLA Antigens | 1 | 2012 | 238 | 0.080 |
Why?
|
| Population Groups | 1 | 2010 | 44 | 0.080 |
Why?
|
| Metabolic Clearance Rate | 1 | 2010 | 118 | 0.080 |
Why?
|
| Stem Cell Transplantation | 1 | 2012 | 194 | 0.080 |
Why?
|
| Chromosomes, Human, X | 1 | 2011 | 56 | 0.080 |
Why?
|
| Population Surveillance | 1 | 2012 | 218 | 0.080 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2010 | 61 | 0.080 |
Why?
|
| Drug Combinations | 1 | 2010 | 201 | 0.080 |
Why?
|
| Cell Line, Transformed | 1 | 2010 | 153 | 0.080 |
Why?
|
| Graft Rejection | 2 | 2016 | 1186 | 0.080 |
Why?
|
| Cell Line | 5 | 2011 | 2483 | 0.080 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2012 | 462 | 0.070 |
Why?
|
| Anthracyclines | 1 | 2009 | 31 | 0.070 |
Why?
|
| Postoperative Complications | 2 | 2016 | 2681 | 0.070 |
Why?
|
| Down-Regulation | 1 | 2010 | 529 | 0.070 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2009 | 136 | 0.070 |
Why?
|
| DNA | 1 | 2014 | 1274 | 0.070 |
Why?
|
| Haplotypes | 1 | 2010 | 656 | 0.070 |
Why?
|
| Creatinine | 1 | 2009 | 313 | 0.070 |
Why?
|
| Immune Complex Diseases | 1 | 2008 | 19 | 0.070 |
Why?
|
| Neutrophil Infiltration | 1 | 2008 | 32 | 0.070 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2008 | 77 | 0.070 |
Why?
|
| Cell Proliferation | 2 | 2010 | 1790 | 0.070 |
Why?
|
| DNA-Binding Proteins | 1 | 2012 | 1255 | 0.060 |
Why?
|
| Fatigue | 2 | 2022 | 187 | 0.060 |
Why?
|
| Genetics, Population | 1 | 2010 | 449 | 0.060 |
Why?
|
| Neurons | 1 | 2015 | 1619 | 0.060 |
Why?
|
| Diabetes Mellitus | 1 | 2013 | 811 | 0.060 |
Why?
|
| Incidence | 1 | 2010 | 1779 | 0.060 |
Why?
|
| Immunosuppressive Agents | 1 | 2010 | 1013 | 0.060 |
Why?
|
| Bridged-Ring Compounds | 1 | 2025 | 16 | 0.060 |
Why?
|
| Kidney Function Tests | 2 | 2016 | 122 | 0.050 |
Why?
|
| Mice, Inbred C57BL | 3 | 2022 | 3603 | 0.050 |
Why?
|
| Taxoids | 1 | 2025 | 127 | 0.050 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2008 | 707 | 0.050 |
Why?
|
| Androgen Receptor Antagonists | 1 | 2024 | 20 | 0.050 |
Why?
|
| Ovarian Neoplasms | 1 | 2011 | 826 | 0.050 |
Why?
|
| Lymph Node Excision | 1 | 2026 | 238 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2016 | 3606 | 0.050 |
Why?
|
| Indazoles | 2 | 2016 | 63 | 0.050 |
Why?
|
| Head and Neck Neoplasms | 1 | 2011 | 1088 | 0.050 |
Why?
|
| Models, Biological | 1 | 2011 | 1807 | 0.050 |
Why?
|
| Receptors, Androgen | 1 | 2024 | 125 | 0.050 |
Why?
|
| Hyperparathyroidism | 1 | 2003 | 65 | 0.050 |
Why?
|
| Dihydrouracil Dehydrogenase (NADP) | 1 | 2023 | 28 | 0.050 |
Why?
|
| Asialoglycoprotein Receptor | 1 | 2023 | 2 | 0.050 |
Why?
|
| Proprotein Convertases | 1 | 2023 | 27 | 0.050 |
Why?
|
| Phthalazines | 1 | 2023 | 58 | 0.050 |
Why?
|
| Leucine | 1 | 2022 | 57 | 0.050 |
Why?
|
| Glomerular Filtration Rate | 2 | 2016 | 299 | 0.050 |
Why?
|
| Parathyroidectomy | 1 | 2003 | 87 | 0.050 |
Why?
|
| Clinical Trials, Phase I as Topic | 2 | 2014 | 153 | 0.050 |
Why?
|
| Pharmacists | 1 | 2022 | 42 | 0.050 |
Why?
|
| Cell Line, Tumor | 3 | 2016 | 2892 | 0.050 |
Why?
|
| Alleles | 2 | 2017 | 1159 | 0.050 |
Why?
|
| Adrenal Insufficiency | 1 | 2022 | 23 | 0.050 |
Why?
|
| Sphingolipids | 1 | 2002 | 21 | 0.050 |
Why?
|
| Vaccines, Synthetic | 1 | 2022 | 59 | 0.050 |
Why?
|
| Reproducibility of Results | 2 | 2021 | 2784 | 0.040 |
Why?
|
| Morpholines | 1 | 2002 | 67 | 0.040 |
Why?
|
| Age Factors | 2 | 2020 | 1962 | 0.040 |
Why?
|
| Antibody Formation | 1 | 2022 | 172 | 0.040 |
Why?
|
| Diet, High-Fat | 1 | 2022 | 143 | 0.040 |
Why?
|
| Drug Synergism | 1 | 2002 | 317 | 0.040 |
Why?
|
| Immunity, Cellular | 1 | 2022 | 187 | 0.040 |
Why?
|
| Ligands | 1 | 2023 | 486 | 0.040 |
Why?
|
| Cholesterol, LDL | 1 | 2023 | 250 | 0.040 |
Why?
|
| Piperazines | 1 | 2023 | 306 | 0.040 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2022 | 173 | 0.040 |
Why?
|
| DNA Damage | 1 | 2023 | 399 | 0.040 |
Why?
|
| Gene Fusion | 1 | 2021 | 41 | 0.040 |
Why?
|
| Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2021 | 67 | 0.040 |
Why?
|
| beta Catenin | 1 | 2022 | 267 | 0.040 |
Why?
|
| Hodgkin Disease | 1 | 2001 | 145 | 0.040 |
Why?
|
| Risk | 2 | 2012 | 660 | 0.040 |
Why?
|
| Bone Marrow Transplantation | 1 | 2001 | 286 | 0.040 |
Why?
|
| Cholesterol | 1 | 2022 | 373 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 1 | 2002 | 1028 | 0.040 |
Why?
|
| Blood Transfusion | 1 | 2001 | 180 | 0.040 |
Why?
|
| Retrospective Studies | 3 | 2024 | 10973 | 0.040 |
Why?
|
| Prostatic Neoplasms | 1 | 2011 | 1836 | 0.040 |
Why?
|
| Antibodies, Viral | 1 | 2022 | 338 | 0.040 |
Why?
|
| Vaccination | 1 | 2022 | 323 | 0.040 |
Why?
|
| Cell Survival | 1 | 2002 | 1014 | 0.040 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2021 | 304 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2023 | 1782 | 0.040 |
Why?
|
| Allografts | 1 | 2020 | 220 | 0.040 |
Why?
|
| Hematopoiesis | 1 | 2020 | 186 | 0.040 |
Why?
|
| Gene Expression | 2 | 2015 | 1320 | 0.040 |
Why?
|
| Blood Platelets | 1 | 2019 | 153 | 0.030 |
Why?
|
| Mice | 3 | 2022 | 12706 | 0.030 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2018 | 109 | 0.030 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2021 | 682 | 0.030 |
Why?
|
| Retreatment | 1 | 2017 | 107 | 0.030 |
Why?
|
| Internationality | 1 | 2017 | 79 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 2017 | 162 | 0.030 |
Why?
|
| BCG Vaccine | 1 | 2017 | 43 | 0.030 |
Why?
|
| Amino Acid Substitution | 1 | 2018 | 334 | 0.030 |
Why?
|
| Social Discrimination | 1 | 2016 | 7 | 0.030 |
Why?
|
| Remission Induction | 1 | 2018 | 754 | 0.030 |
Why?
|
| DNA Mutational Analysis | 1 | 2018 | 548 | 0.030 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2017 | 141 | 0.030 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2016 | 86 | 0.030 |
Why?
|
| Employment | 1 | 2016 | 66 | 0.030 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2016 | 66 | 0.030 |
Why?
|
| Europe | 1 | 2016 | 356 | 0.030 |
Why?
|
| Cholesterol, Dietary | 1 | 2015 | 27 | 0.030 |
Why?
|
| Transplants | 1 | 2016 | 43 | 0.030 |
Why?
|
| E-Selectin | 1 | 2015 | 31 | 0.030 |
Why?
|
| Child | 3 | 2016 | 7681 | 0.030 |
Why?
|
| Carotid Artery Injuries | 1 | 2015 | 22 | 0.030 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 2015 | 39 | 0.030 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2018 | 452 | 0.030 |
Why?
|
| Receptors, LDL | 1 | 2015 | 54 | 0.030 |
Why?
|
| Glycoside Hydrolase Inhibitors | 1 | 2015 | 1 | 0.030 |
Why?
|
| 1-Deoxynojirimycin | 1 | 2015 | 3 | 0.030 |
Why?
|
| RNA Polymerase II | 1 | 2015 | 63 | 0.030 |
Why?
|
| Protein Interaction Mapping | 1 | 2015 | 79 | 0.030 |
Why?
|
| Netrin Receptors | 1 | 2014 | 7 | 0.030 |
Why?
|
| Lentivirus | 1 | 2015 | 44 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2016 | 674 | 0.030 |
Why?
|
| Primary Cell Culture | 1 | 2015 | 84 | 0.030 |
Why?
|
| Hyperglycemia | 1 | 2016 | 186 | 0.030 |
Why?
|
| Microsomes, Liver | 1 | 2014 | 48 | 0.030 |
Why?
|
| Transgenes | 1 | 2015 | 173 | 0.030 |
Why?
|
| Transduction, Genetic | 1 | 2015 | 161 | 0.030 |
Why?
|
| Transplant Recipients | 1 | 2016 | 182 | 0.030 |
Why?
|
| Plasmids | 1 | 2015 | 275 | 0.030 |
Why?
|
| Social Support | 1 | 2016 | 246 | 0.030 |
Why?
|
| Recurrence | 2 | 2011 | 1254 | 0.030 |
Why?
|
| Reference Standards | 1 | 2014 | 146 | 0.030 |
Why?
|
| Ireland | 1 | 2013 | 12 | 0.020 |
Why?
|
| Nephrectomy | 1 | 2016 | 290 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2014 | 402 | 0.020 |
Why?
|
| Genetic Vectors | 1 | 2015 | 426 | 0.020 |
Why?
|
| Societies, Medical | 1 | 2017 | 682 | 0.020 |
Why?
|
| Multicenter Studies as Topic | 1 | 2013 | 200 | 0.020 |
Why?
|
| Animals | 3 | 2022 | 28904 | 0.020 |
Why?
|
| Transplantation Chimera | 1 | 2012 | 84 | 0.020 |
Why?
|
| United States Department of Defense | 1 | 2011 | 4 | 0.020 |
Why?
|
| Endothelial Cells | 1 | 2015 | 500 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2015 | 977 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2016 | 1815 | 0.020 |
Why?
|
| Early Termination of Clinical Trials | 1 | 2011 | 16 | 0.020 |
Why?
|
| Nerve Tissue Proteins | 1 | 2015 | 512 | 0.020 |
Why?
|
| Graft Survival | 1 | 2016 | 994 | 0.020 |
Why?
|
| Orchiectomy | 1 | 2011 | 64 | 0.020 |
Why?
|
| Contrast Media | 1 | 2016 | 1011 | 0.020 |
Why?
|
| Students | 1 | 2013 | 196 | 0.020 |
Why?
|
| Transplantation, Autologous | 2 | 2003 | 395 | 0.020 |
Why?
|
| Action Potentials | 1 | 2015 | 611 | 0.020 |
Why?
|
| Insulin | 1 | 2016 | 1225 | 0.020 |
Why?
|
| Genes, X-Linked | 1 | 2011 | 39 | 0.020 |
Why?
|
| Diarrhea | 1 | 2011 | 180 | 0.020 |
Why?
|
| Computational Biology | 1 | 2014 | 614 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 2015 | 1133 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2012 | 922 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2015 | 2855 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2015 | 2209 | 0.020 |
Why?
|
| Patient Compliance | 1 | 2011 | 245 | 0.020 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2011 | 262 | 0.020 |
Why?
|
| Herpesvirus 4, Human | 1 | 2010 | 125 | 0.020 |
Why?
|
| Laparoscopy | 1 | 2016 | 791 | 0.020 |
Why?
|
| Adenosine Triphosphate | 1 | 2010 | 319 | 0.020 |
Why?
|
| Quality Improvement | 1 | 2013 | 520 | 0.020 |
Why?
|
| Macrophage-1 Antigen | 1 | 2008 | 18 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2014 | 2013 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 2011 | 551 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2015 | 1646 | 0.020 |
Why?
|
| Receptors, IgG | 1 | 2008 | 70 | 0.020 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2016 | 1286 | 0.020 |
Why?
|
| Registries | 1 | 2013 | 1122 | 0.020 |
Why?
|
| Bone Marrow Cells | 1 | 2008 | 269 | 0.020 |
Why?
|
| Cell Adhesion | 1 | 2008 | 419 | 0.020 |
Why?
|
| Transcription Factors | 1 | 2015 | 1717 | 0.020 |
Why?
|
| Physicians | 1 | 2013 | 685 | 0.010 |
Why?
|
| Gene Expression Profiling | 1 | 2011 | 1565 | 0.010 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2011 | 849 | 0.010 |
Why?
|
| Biomarkers | 1 | 2011 | 2020 | 0.010 |
Why?
|
| Baltimore | 1 | 2001 | 42 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2001 | 1284 | 0.010 |
Why?
|